Why vendor and CDMO qualification cannot be informal
If a contract manufacturer, testing laboratory, packaging site, or critical material supplier sits in your supply chain, their failures become your regulatory problem. FDA, EMA, and other authorities expect sponsors and product owners to qualify vendors and to keep that oversight current. A desk review of a questionnaire is rarely enough for a high-risk CMO, CDMO, or supplier.
GxP Auditing and Consulting Services performs supplier, vendor, CMO, and CDMO qualification audits led by Ramzi W. Kozal, CQA, an independent GxP lead auditor with nearly 30 years of experience and 300+ GxP audits led across the US and Europe, including Italy. The work is designed to answer a practical question: is this partner qualified for the activity you are about to entrust to them, and what must be fixed before you rely on them?
What a qualification audit typically covers
The scope follows the risk of the vendor and the work they will do. A CDMO making a sterile or radiopharmaceutical product is not audited the same way as a lower-risk component supplier. In general, a qualification audit reviews:
• The vendor’s quality system, including deviations, CAPA, change control, training, and document control
• Manufacturing, laboratory, or packaging practices applicable to the contracted activity
• Data integrity controls and, where relevant, computerized systems and 21 CFR Part 11 expectations
• Facilities, utilities, and environmental or radiation-safety controls when those are part of the process
• Quality agreements, specifications, and how the vendor will communicate deviations or changes
• The supplier’s own vendor controls, when your product depends on their upstream materials
For pharmaceutical and biologic manufacturing partners, the audit frame is typically GMP under 21 CFR Parts 210 and 211, and related expectations for laboratory controls and batch documentation. Radiopharmaceutical and PET drug partners are assessed with 21 CFR Part 212 in mind. Dietary supplement suppliers may be assessed under 21 CFR Part 111.
The same independent auditor also performs related GLP and GDP audits when the vendor is a laboratory or a distribution partner rather than a manufacturer.
CMO and CDMO oversight after the first audit
Qualification is not a one-time event. After an initial audit, many companies need periodic requalification, for-cause audits, or support reviewing CAPA that came out of the first visit. Ongoing CMO and CDMO oversight can include follow-up on serious deviations, checks that quality agreements are actually being followed, and targeted reviews when a process, site, or data system changes.
This is often where an independent lead auditor is most useful. You get a senior reviewer who is not part of the vendor’s quality unit and is not negotiating the commercial contract, so the findings can stay focused on compliance risk.
What you receive
A typical vendor or CDMO engagement produces a defined scope, an audit plan, and a written report with findings categorized by risk. The report is meant to be usable: it should support a qualification decision, a quality agreement discussion, and a CAPA plan. A follow-up discussion is included so your team can decide what must be closed before approval, what can be managed as a residual risk, and when a revisit is warranted.
On-site audits are available across the US and internationally, and remote audits are available worldwide. Remote audits can be effective when the risk is document-heavy and the vendor can provide records, interviews, and video or system access in a controlled way. On-site work remains the better choice for complex manufacturing, aseptic operations, radiopharma facilities, or situations where the facility itself is the main risk.
​
When to bring in an independent qualification auditor
Companies usually ask for this work when they are selecting a new CMO or CDMO, expanding a product into a new site, responding to a quality event at a supplier, or preparing for an inspection in which investigator questions about vendor control are likely. It is also used when internal auditor capacity is limited, or when independence from both the vendor and the commercial relationship is important.
If you need a CRO qualified under GCP rather than a manufacturing partner, see the CRO and GCP qualification audit page. If the vendor issue is really a data integrity or computerized-system problem, the data integrity and CSV page is the better starting point.
To scope a vendor, CMO, or CDMO qualification audit, contact GxP Auditing and Consulting Services or call (239) 207-8132. Pricing for vendor audit packages and related add-ons is listed on the pricing page.
Frequently Asked Questions
Do you audit only manufacturing vendors?
No. Qualification audits can cover CMOs, CDMOs, material and packaging suppliers, laboratories, and distribution partners. Manufacturing partners are often assessed under GMP. Laboratories and supply-chain partners may be assessed under GLP or GDP, depending on the activity.
​
Can you audit a CDMO that works in radiopharma or advanced biologics?
Yes. The practice includes 21 CFR Part 212 radiopharmaceutical and PET drug audits, as well as work with cell and gene therapy, mRNA drug substance, and LNP drug product platforms.
​
Is a remote vendor audit acceptable?
It can be, when the risks are understood and the vendor can provide the records and interviews needed. On-site audits are recommended for higher-risk manufacturing, aseptic processing, and radiopharmaceutical operations.
​
What do we receive at the end of the audit?
You receive a written report with risk-ranked findings and a discussion of next steps, including what should be resolved before qualification and where follow-up or a quality agreement change may be needed.
​
How is this different from a CRO audit?
CMO and CDMO audits are usually GMP or related manufacturing and quality-system assessments. CRO qualification is a GCP activity under ICH E6 and, for U.S. drug studies, 21 CFR 312. That work is described on the CRO and GCP qualification audits page.
_edited.png)